Related Experiment Video

Updated: Jun 12, 2026

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

[mTOR inhibitors]

Mototsugu Oya1

  • 1Department of Urology, Keio University School of Medicine.

Nihon Rinsho. Japanese Journal of Clinical Medicine
|June 12, 2010
PubMed

Insights

Mammalian target of rapamycin (mTOR) inhibitors show promise for cancer treatment, particularly metastatic renal cell carcinoma (RCC). While effective, interstitial pneumonia is a significant adverse event requiring monitoring.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • The mammalian target of rapamycin (mTOR) protein complex integrates signaling pathways crucial for cell proliferation, survival, and angiogenesis.
  • Aberrant regulation of these pathways, particularly involving Akt, is common in various cancers.
  • mTOR inhibitors represent a therapeutic strategy for managing cancer.

Purpose of the Study:

  • To review the current applications and potential of mTOR inhibitors in cancer therapy.
  • To highlight the use of mTOR inhibitors in metastatic renal cell carcinoma (RCC).
  • To discuss the adverse events associated with mTOR inhibitors.

Main Methods:

  • Review of current clinical applications of mTOR inhibitors.
  • Analysis of treatment guidelines for metastatic RCC using mTOR inhibitors.
  • Summary of reported adverse events, focusing on interstitial pneumonia.

Main Results:

  • mTOR inhibitors are currently approved for metastatic RCC treatment.
  • Temsirolimus is a first-line option for poor-prognosis RCC patients.
  • Everolimus is a second-line option for patients resistant to sorafenib or sunitinib.

Conclusions:

  • mTOR inhibitors are valuable therapeutic agents for specific cancer types, notably RCC.
  • Interstitial pneumonia is a critical adverse event associated with temsirolimus and everolimus.
  • Ongoing clinical trials are investigating broader applications of mTOR inhibitors across various cancers.

More Related Videos

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...